Loading ...

The recent FDA approval of a first-in-class aldosterone synthase inhibitor may help usher in a new era of treatment for hypertension, according to some clinicians. 

Baxdrostat (Baxfendy, AstraZeneca) was approved to lower blood pressure (BP) in combination with other antihypertensives in patients with uncontrolled hypertension. It works by targeting the production of aldosterone — a BP-raising hormone that can increase the risk for heart and kidney disorders.

For decades, cardiologists and other clinicians have managed hypertension by layering conventional antihypertensive drug classes, such as angiotensin-converting enzyme inhibitors, calcium channel blockers, and beta-blockers. But with baxdrostat’s addition to the armamentarium, some clinicians believe hypertension treatment may be moving toward a more precision-based model of care, increasingly seen in other fields such as oncology.

Matthew Tomey, MD, cardiologist at Mount Sinai Fuster Heart Hospital in New York City, applauded this evolution. “The emergence of therapies targeting pathways such as aldosterone signaling may mark a shift toward more biologically targeted treatment of hypertension, particularly in patients with resistant disease,” he said.

The BaxHTN Phase 3 Trial

The agency based baxdrostat’s approval on findings from the BaxHTN phase 3 trial, which was published in The New England Journal of Medicine and presented at the European Society of Cardiology (ESC) Congress in August 2025.

The multinational trial was randomized, double-blind, and placebo-controlled. It was conducted from November 2023 through February 2025, evaluating baxdrostat in patients with uncontrolled or resistant hypertension.

In the trial, those taking baxdrostat 1 mg saw their systolic BP drop by 14.5 points, and those taking 2 mg saw a 15.7-point reduction in systolic BP compared with 5.8 points in the placebo group after 12 weeks.

Adverse events were generally mild, although researchers noted more electrolyte abnormalities, including hyperkalemia and hyponatremia, with baxdrostat than with placebo. No cases of adrenal insufficiency were reported.

Precision Medicine for Hypertension?

Baxdrostat may represent part of a larger shift away from treating hypertension solely with broad antihypertensive drug classes and toward targeting specific biologic drivers of the disease, such as aldosterone.

A 2023 study published in the journal Hypertension looked at the progress made toward precision medicine for hypertension. Researchers found that advances in large datasets, including clinical, health-related, and behavioral and environmental sources, were promising for achieving predictive approaches to more personalized health management.

Additionally, they noted, “The emerging science of AI may further advance the concept of precision hypertension in discovery, drug targeting and development, patient care, and management.”

Medication Access for Physicians, Patients

Luke J. Laffin, MD, co-director of the Center for Blood Pressure Disorders at the Cleveland Clinic, believes this medication can move the needle forward in treating a disorder that remains difficult to control, but with a bureaucratic caveat.

“My hope is that we are entering an era where we can achieve better blood pressure control rates, given that some estimates suggest less than 30% of patients with hypertension in the United States have their blood pressure controlled,” Laffin said.

“A major question that remains unanswered is how easily patients will be able to access new, nongeneric medications to treat hypertension,” he said. “The field has so many generic drugs that the hoops clinicians will need to go through after prescribing baxdrostat, such as step therapy or prior authorization, remain unclear.”

Tomey reported having no relevant financial relationships.

Laffin disclosed serving as a consultant and member of the steering committees for Recor, Medtronic, Eli Lilly and Company, Mineralys Therapeutics, CRISPR Therapeutics, Novartis, Novo Nordisk, Ripple Medical, and Stability Health. He also reported receiving research funding from AstraZeneca, Arrowhead, Retension, and Kardigan and receiving royalties from Belvoir Media Group and Elsevier.

Lois Anzelowitz Levine is a medical and lifestyle writer who lives in Dallas.